BONUSCAP-ZERTIFIKAT - BIOGEN IDEC | Real-time BOERSE MUENCHEN 03:45:05 2024-06-03 EDT | ||
| 307.9 EUR | +0.03% |
|
| 1 month | +6.37% | ||
| 3 months | +6.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 307.9 | +0.03% |
| 24-05-31 | 307.8 | +2.70% |
| 24-05-30 | 299.7 | +2.29% |
| 24-05-29 | 293 | -1.45% |
| 24-05-28 | 297.3 | +0.02% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 03:45 am
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC8B8D |
| ISIN | DE000HC8B8D3 |
| Date issued | 2023-07-28 |
| Strike | 340 $ |
| Maturity | 2024-12-20 (201 Days) |
| Parity | 1 : 1 |
| Emission price | 290.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 311.4 € |
|---|---|
| Lowest since issue | 222.6 € |
| Spread | 0.83 € |
| Spread % | 0.27% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Certificates
- Certificat
